scholarly journals Modular micro-physiological human tumor/tissue models based on decellularized tissue for improved preclinical testing

ALTEX ◽  
2020 ◽  
Author(s):  
Johanna Kühnemundt
Keyword(s):  
Tumor Tissue ◽  
Human Tumor ◽  
Preclinical Testing ◽  
Decellularized Tissue ◽  
Tissue Models

A report of sex chromatin in human tumor tissue culture

1958 ◽  
Vol 15 (1) ◽  
pp. 244-246 ◽  
Author(s):  
E.V. Orsi ◽  
H.B. Ritter
Keyword(s):  
Tissue Culture ◽  
Tumor Tissue ◽  
Human Tumor ◽  
Sex Chromatin

scholarly journals Human Tumor Tissue-Based 3D In Vitro Invasion Assays

2018 ◽  
pp. 213-221 ◽  
Author(s):  
Pirjo Åström ◽  
Ritva Heljasvaara ◽  
Pia Nyberg ◽  
Ahmed Al-Samadi ◽  
Tuula Salo
Keyword(s):  
Tumor Tissue ◽  
Human Tumor ◽  
In Vitro Invasion ◽  
Invasion Assays

scholarly journals SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner

2020 ◽  
Vol 21 (2) ◽  
pp. 596 ◽  
Author(s):  
Helena Ramos ◽  
Juliana Calheiros ◽  
Joana Almeida ◽  
Valentina Barcherini ◽  
Sónia Santos ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Cytochrome C ◽  
Cancer Cells ◽  
Cytochrome C Oxidase ◽  
Tumor Tissue ◽  
Human Tumor ◽  
Dichloroacetic Acid ◽  
Dependent Manner ◽  
Glucose Transporter 1 ◽  
Expression Levels

The Warburg effect is an emerging hallmark of cancer, which has the tumor suppressor p53 as its major regulator. Herein, we unveiled that p53 activation by (S)-tryptophanol-derived oxazoloisoindolinone (SLMP53-1) mediated the reprograming of glucose metabolism in cancer cells and xenograft human tumor tissue, interfering with angiogenesis and migration. Particularly, we showed that SLMP53-1 regulated glycolysis by downregulating glucose transporter 1 (GLUT1), hexokinase-2 (HK2), and phosphofructokinase-2 isoform 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-3 (PFKFB3) (key glycolytic enzymes), while upregulating the mitochondrial markers synthesis of cytochrome c oxidase 2 (SCO2), cytochrome c oxidase subunit 4 (COX4), and OXPHOS mitochondrial complexes. SLMP53-1 also downregulated the monocarboxylate transporter 4 (MCT4), causing the subsequent reduction of lactate export by cancer cells. Besides the acidification of the extracellular environment, SLMP53-1 further increased E-cadherin and reduced metalloproteinase-9 (MMP-9) expression levels in both cancer cells and xenograft human tumor tissue, which suggested the interference of SLMP53-1 in extracellular matrix remodeling and epithelial-to-mesenchymal transition. Consistently, SLMP53-1 depleted angiogenesis, decreasing endothelial cell tube formation and vascular endothelial growth factor (VEGF) expression levels. SLMP53-1 also exhibited synergistic growth inhibitory activity in combination with the metabolic modulator dichloroacetic acid. These data reinforce the promising application of the p53-activating agent SLMP53-1 in cancer therapy, by targeting p53-mediated pathways of growth and dissemination.

Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules

Vaccine ◽  
2001 ◽  
Vol 19 (15-16) ◽  
pp. 2029-2038 ◽  
Author(s):  
Neil J Poloso ◽  
Shanmugam Nagarajan ◽  
Gary W Bumgarner ◽  
Periasamy Selvaraj
Keyword(s):  
Cell Membranes ◽  
Tumor Tissue ◽  
Human Tumor ◽  
Therapeutic Vaccines ◽  
Direct Modification
Sign in / Sign up

Export Citation Format

Share Document